Literature DB >> 26180772

Sulfonylureas: Asset or liability?

Om J Lakhani1, Jitendra D Lakhani2.   

Abstract

Entities:  

Year:  2015        PMID： 26180772      PMCID： PMC4481663          DOI： 10.4103/2230-8210.159066

Source DB:  PubMed          Journal:  Indian J Endocrinol Metab        ISSN： 2230-9500


× No keyword cloud information.
  4 in total

1.  AACE comprehensive diabetes management algorithm 2013.

Authors:  Alan J Garber; Martin J Abrahamson; Joshua I Barzilay; Lawrence Blonde; Zachary T Bloomgarden; Michael A Bush; Samuel Dagogo-Jack; Michael B Davidson; Daniel Einhorn; W Timothy Garvey; George Grunberger; Yehuda Handelsman; Irl B Hirsch; Paul S Jellinger; Janet B McGill; Jeffrey I Mechanick; Paul D Rosenblit; Guillermo Umpierrez; Michael H Davidson
Journal:  Endocr Pract       Date:  2013 Mar-Apr       Impact factor: 3.443

2.  Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes.

Authors:  Silvio E Inzucchi; Richard M Bergenstal; John B Buse; Michaela Diamant; Ele Ferrannini; Michael Nauck; Anne L Peters; Apostolos Tsapas; Richard Wender; David R Matthews
Journal:  Diabetologia       Date:  2015-01-13       Impact factor: 10.122

3.  Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes.

Authors:  Jeffrey A Johnson; Sumit R Majumdar; Scot H Simpson; Ellen L Toth
Journal:  Diabetes Care       Date:  2002-12       Impact factor: 19.112

4.  Sulfonylureas: Assets in the past, present and future.

Authors:  Sanjay Kalra; S V Madhu; Sarita Bajaj
Journal:  Indian J Endocrinol Metab       Date:  2015 May-Jun
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.